Vistagen's Fasedienol Misses Primary Endpoint but Shows Promise in Severe Social Anxiety Subgroup
Event summary
- Vistagen's PALISADE-4 Phase 3 trial of fasedienol for social anxiety disorder missed its primary endpoint, showing no significant difference from placebo in the overall population.
- Post-hoc analysis revealed a statistically significant efficacy signal in a subgroup of patients with very severe social anxiety (LSAS ≥95).
- Vistagen plans to shift focus from acute treatment to overall treatment of social anxiety disorder, aiming for a single multi-dose Phase 3 trial with LSAS as the primary endpoint.
- The company expects its cash resources to support operations into 2027.
The big picture
Vistagen's shift from acute to chronic treatment of social anxiety disorder reflects broader industry trends toward more comprehensive therapeutic approaches. The company's focus on nose-to-brain neurocircuitry differentiates its pipeline, but success will depend on navigating regulatory expectations and demonstrating consistent efficacy across patient subgroups.
What we're watching
- Regulatory Strategy
- Whether Vistagen can secure FDA agreement on a revised registrational pathway focused on overall treatment of social anxiety disorder.
- Subgroup Validation
- How the efficacy signal in severe social anxiety patients will be further validated or challenged in future trials.
- Financial Runway
- The pace at which Vistagen can advance its pipeline while maintaining financial discipline and extending cash resources beyond 2027.